Zelboraf 240 mg (Vemurafenib TABLET) 240 MG

ZELBORAF 240 MG tablets contain vemurafenib, a medication used in cancer treatment. This oral tablet is manufactured by Hoffmann-La Roche Limited in Canada.

Strength

240 MG

Pack Size

Manufacturer / TM Owner

HOFFMANN-LA ROCHE LIMITED

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

ZELBORAF 240 MG tablets are primarily used in the treatment of certain types of cancer. Vemurafenib, the active ingredient, is often prescribed for advanced melanoma with a specific genetic mutation. Patients may wonder, 'What is vemurafenib used for?' It is designed to target and inhibit the growth of cancer cells, offering a targeted approach to cancer therapy.

Side Effects

Common effects of ZELBORAF 240 MG tablets may include skin-related issues such as rash, itching, or sun sensitivity. Some users might experience fatigue, joint pain, or changes in hair color. It's important to monitor for any unusual symptoms and consult a healthcare provider if concerns arise.

Precautions & Warnings

Handling ZELBORAF 240 MG tablets requires careful consideration of potential side effects and interactions. Patients should avoid excessive sun exposure due to increased skin sensitivity. Regular medical check-ups are advisable to monitor treatment progress and manage any adverse effects effectively.

Avoid Interactions

ZELBORAF 240 MG tablets may interact with certain medications, including those metabolized by the liver's CYP enzymes. Alcohol consumption should be discussed with a healthcare provider, as it may affect the efficacy or safety of the treatment. Always inform your healthcare provider about all medications you are taking to avoid potential interactions.

References

Frequently Asked Questions

Vemurafenib is used in the treatment of certain types of cancer, particularly advanced melanoma with a specific genetic mutation.

ZELBORAF 240 MG tablets should be stored at room temperature, away from moisture and heat.

Common side effects may include skin rash, fatigue, joint pain, and increased sensitivity to sunlight.

Always consult a healthcare provider before taking ZELBORAF 240 MG tablets with other medications to avoid potential interactions.

Vemurafenib is specifically indicated for certain types of cancer and should be used as directed by a healthcare provider.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.